A higher percentage of participants with serum prokineticin-2 levels >6.32 ng/ml had history of lipid disorders, and MS than those with prokineticin-2 ≤ 6.32 (both P < 0.01). The gene discussed is PROK2; the disease is myeloid sarcoma.